Practical insights on deal-making covering licensing, partnering and M&A in the pharmaceutical, biotechnology, diagnostics and medical devices sector -get acquainted with state-of-the-art concepts and practices.
Mastering the Valuation of Pharma and Biotech Assets and Businesses Properly valuing drug and biotechnology assets is essential for pharmaceutical enterprises, biotech companies, investors, and other healthcare stakeholders. Valuation provides…
Essential Strategies for Successful Out-Licensing and Partnering in Pharma and Biotech Industry Dealmaking in the pharmaceutical and biotech industries plays a pivotal role in fostering growth and innovation. Partnering and…
Pharmaceutical R&D Trends 2025: Key Insights and Strategic Shifts The pharmaceutical industry is at a critical inflection point in 2025, with research and development (R&D) continuing to grow despite global…
Key Success Factor in Pharma Search and Evaluation and Due Diligence Licensing and partnering are critical growth strategies in the biopharma industry. The effectiveness of licensing and partnership relies heavily on…
Enhancing Biopharma Licensing and Partnering Through Comparative Evaluation The biopharmaceutical industry landscape is constantly evolving, and in-licensing and partnering deals are vital corporate strategies for driving innovation, devising new products,…
Leveraging EBITDA Multiples for Accurate Pharma Company Valuations Determining the valuation of pharmaceutical and biotechnology companies is a crucial exercise to inform high-impact decisions including organic investments and prioritization, licensing…
Leveraging Biotech Valuation Multiples for Accurate Biopharma Company Valuations Valuation of biotech companies, assets, and programs is often required for a multitude of purposes. The biotech valuation multiples is a…
Criteria and Strategies for Choosing the Right Comparable Companies in Biotech Valuation When valuing a private or public biotech company using market multiples, one of the most critical first steps…
Proven Strategies to Speed Up Biotech and Pharma Partnering & Out-Licensing Deals Are you frustrated with the slow and time-consuming process of out-licensing biopharma assets? The good news is that…
How to Expedite Biotech Partnering & Out-Licensing Deals by Looking Beyond Traditional Prospects Partnering and out-licensing are central to the growth of life sciences companies, especially for emerging pharmaceutical and…